126 related articles for article (PubMed ID: 37533334)
1. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
Kim TH; Rodriguez EF; Lim D; Moatamed NA
Diagn Cytopathol; 2023 Nov; 51(11):705-711. PubMed ID: 37533334
[TBL] [Abstract][Full Text] [Related]
2. Copy number variations identified in thyroid FNA specimens are associated with Hürthle cell cytomorphology.
Abi-Raad R; Prasad ML; Adeniran AJ; Cai G
Cancer Cytopathol; 2022 Jun; 130(6):415-422. PubMed ID: 35332982
[TBL] [Abstract][Full Text] [Related]
3. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
4. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
[TBL] [Abstract][Full Text] [Related]
6. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
7. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
8. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
Wong KS; Jo VY; Lowe AC; Faquin WC; Renshaw AA; Shah AA; Roh MH; Stelow EB; Krane JF
Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
[TBL] [Abstract][Full Text] [Related]
9. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
10. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
Straccia P; Rossi ED; Bizzarro T; Brunelli C; Cianfrini F; Damiani D; Fadda G
Cancer Cytopathol; 2015 Dec; 123(12):713-22. PubMed ID: 26355876
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
Doerfler WR; Nikitski AV; Morariu EM; Ohori NP; Chiosea SI; Landau MS; Nikiforova MN; Nikiforov YE; Yip L; Manroa P
Endocr Relat Cancer; 2021 Apr; 28(5):301-309. PubMed ID: 33792557
[TBL] [Abstract][Full Text] [Related]
12. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
13. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
Gajzer DC; Tjendra Y; Kerr DA; Algashaamy K; Zuo Y; Menendez SG; Jorda M; Garcia-Buitrago M; Gomez-Fernandez C; Velez Torres JM
Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
[TBL] [Abstract][Full Text] [Related]
14. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology.
Broome JT; Solorzano CC
Surgery; 2011 Dec; 150(6):1234-41. PubMed ID: 22136846
[TBL] [Abstract][Full Text] [Related]
15. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
[TBL] [Abstract][Full Text] [Related]
16. Cytotechnologist Performance for Screening Hürthle Cell Atypia in Indeterminate Thyroid Fine-Needle Aspirates.
VandenBussche CJ; Adams C; Ali SZ; Olson MT
Acta Cytol; 2015; 59(5):377-83. PubMed ID: 26606302
[TBL] [Abstract][Full Text] [Related]
17. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
[TBL] [Abstract][Full Text] [Related]
18. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
19. The Bethesda terminology for reporting thyroid cytopathology: from theory to practice in Europe.
Cochand-Priollet B; Schmitt FC; Tötsch M; Vielh P;
Acta Cytol; 2011; 55(6):507-11. PubMed ID: 22156458
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study of Clinicopathologic Outcomes of Nodules With Hürthle Cell Cytology and the Thyroid Nodule App (TNAPP) Ultrasound Recommendations.
Spagnuolo GM; Tierney HT; Laver NMV; Eldeiry LS
Endocr Pract; 2022 Jun; 28(6):593-598. PubMed ID: 35307577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
